Literature DB >> 27413802

Drug-like Antagonists of P2Y Receptors-From Lead Identification to Drug Development.

Sean Conroy1, Nicholas Kindon1, Barrie Kellam1, Michael J Stocks1.   

Abstract

P2Y receptors are expressed in virtually all cells and tissue types and mediate an astonishing array of biological functions, including platelet aggregation, smooth muscle cell proliferation, and immune regulation. The P2Y receptors belong to the G protein-coupled receptor superfamily and are composed of eight members encoded by distinct genes that can be subdivided into two groups on the basis of their coupling to specific G-proteins. Extensive research has been undertaken to find modulators of P2Y receptors, although to date only a limited number of small-molecule P2Y receptor antagonists have been approved by drug/medicines agencies. This Perspective reviews the known P2Y receptor antagonists, highlighting oral drug-like receptor antagonists, and considers future opportunities for the development of small molecules for clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27413802     DOI: 10.1021/acs.jmedchem.5b01972

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design.

Authors:  Antonella Ciancetta; Kenneth A Jacobson
Journal:  Methods Mol Biol       Date:  2018

2.  Synthesis and biological evaluation of N 6 derivatives of 8-azapurine as novel antiplatelet agents.

Authors:  Zhichang Zhao; Yeming Wang; Nana Tian; Hong Yan; Juan Wang
Journal:  RSC Med Chem       Date:  2021-07-13

3.  Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y2 Receptor Based on AR-C118925.

Authors:  Sean Conroy; Nicholas D Kindon; Jacqueline Glenn; Leigh A Stoddart; Richard J Lewis; Stephen J Hill; Barrie Kellam; Michael J Stocks
Journal:  J Med Chem       Date:  2018-03-28       Impact factor: 7.446

4.  Nucleotide P2Y1 receptor agonists are in vitro and in vivo prodrugs of A1/A3 adenosine receptor agonists: implications for roles of P2Y1 and A1/A3 receptors in physiology and pathology.

Authors:  Theodore E Liston; Sonja Hinz; Christa E Müller; Deborah M Holstein; Jay Wendling; Roger J Melton; Mary Campbell; William S Korinek; R Rama Suresh; Dane A Sethre-Hofstad; Zhan-Guo Gao; Dilip K Tosh; Kenneth A Jacobson; James D Lechleiter
Journal:  Purinergic Signal       Date:  2020-10-31       Impact factor: 3.765

5.  Structure-Guided Modification of Heterocyclic Antagonists of the P2Y14 Receptor.

Authors:  Jinha Yu; Antonella Ciancetta; Steven Dudas; Sierra Duca; Justine Lottermoser; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2018-05-16       Impact factor: 7.446

Review 6.  Purinergic Signaling: Impact of GPCR Structures on Rational Drug Design.

Authors:  Veronica Salmaso; Kenneth A Jacobson
Journal:  ChemMedChem       Date:  2020-09-18       Impact factor: 3.540

Review 7.  Update of P2Y receptor pharmacology: IUPHAR Review 27.

Authors:  Kenneth A Jacobson; Esmerilda G Delicado; Christian Gachet; Charles Kennedy; Ivar von Kügelgen; Beibei Li; M Teresa Miras-Portugal; Ivana Novak; Torsten Schöneberg; Raquel Perez-Sen; Doreen Thor; Beili Wu; Zhenlin Yang; Christa E Müller
Journal:  Br J Pharmacol       Date:  2020-04-06       Impact factor: 9.473

Review 8.  Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases.

Authors:  Diego Dal Ben; Luca Antonioli; Catia Lambertucci; Matteo Fornai; Corrado Blandizzi; Rosaria Volpini
Journal:  Front Pharmacol       Date:  2018-03-14       Impact factor: 5.810

9.  P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis.

Authors:  Jennifer Patritti Cram; Jianqiang Wu; Robert A Coover; Tilat A Rizvi; Katherine E Chaney; Ramya Ravindran; Jose A Cancelas; Robert J Spinner; Nancy Ratner
Journal:  Elife       Date:  2022-03-21       Impact factor: 8.140

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.